Cytokine Profile as a Marker of Cell Damage and Immune Dysfunction after Spinal Cord Injury

Telegin, G. B.; Chernov, Aleksandr S.; Belogurov, A. A.; Балмасова, И П; Коновалов, Н. А.; Gabibov, A. G.

doi:10.5772/intechopen.95614

Cited by 1 publication

(1 citation statement)

References 119 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study of specific immune subsets obtained from the peripheral blood of patients with chronic SCI has received increasing attention in recent years. Along these lines, previous works have identified altered levels of multiple serum cytokines and immune populations in patients with SCI [ 16 , 17 ]. For instance, we showed that enhanced markers of intestinal barrier dysfunction and inflammatory markers such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) can be observed in patients with chronic SCI, which are associated with impaired function of circulating monocyte [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Patients with Chronic Spinal Cord Injury and a Long Period of Evolution Exhibit an Altered Cytokine Production by CD4 and CD8 T Cell Populations

Girón

Gómez-Lahoz

Monserrat

et al. 2023

IJMS

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a disabling neurological condition coursing with serious multisystem affections and morbidities. Changes in immune cell compartments have been consistently reported in previous works, representing a critical point of study for understanding the pathophysiology and progression of SCI from acute to chronic stages. Some relevant variations in circulating T cells have been noticed in patients with chronic SCI, although the number, distribution, and function of these populations remain to be fully elucidated. Likewise, the characterization of specific T cell subpopulations and their related cytokine production can aid in understanding the immunopathological role of T cells in SCI progression. In this sense, the objective of the present study was to analyze and quantify the total number of different cytokine-producers T cells in the serum of patients with chronic SCI (n = 105) in comparison to healthy controls (n = 38) by polychromatic flow cytometry. Having this goal, we studied CD4 and CD8 lymphocytes as well as naïve, effector, and effector/central memory subpopulations. SCI patients were classified according to the duration of the lesion in chronic SCI with a short period of evolution (SCI-SP) (comprised between 1 and 5 years since initial injury), early chronic phase (SCI-ECP) (between 5 and 15 years since initial injury) and late-chronic phase (SCI-LCP) (>15 years since initial injury). Our results show that patients with chronic SCI exhibited an altered immune profile of cytokine-producer T cells, including CD4/CD8 naïve, effector, and memory subpopulations in comparison to HC. In particular, IL-10 and IL-9 production seems to be importantly altered, especially in patients with SCI-LCP, whereas changes in IL-17, TNF-α, and IFN-γ T cell populations have also been reported in this and other chronic SCI groups. In conclusion, our study demonstrates an altered profile of cytokine-producer T cells in patients with chronic SCI, with marked changes throughout the course of the disease. In more detail, we have observed significant variations in cytokine production by circulating naive, effector, and effector/central memory CD4 and CD8 T cells. Future studies should be directed to explore the possible clinical consequences of these changes or develop additional translational approaches in these groups of patients.

show abstract

Section: Introductionmentioning

confidence: 99%